Democratising access to quantum computing: IQM Quantum Computers launches “IQM Spark” for universities and labs
30.8.2023 11:55:00 EEST | Business Wire | Press release
IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830120669/en/
IQM Spark quantum computer (Photo: Business Wire)
IQM Spark comes pre-installed with a 5-qubit quantum processing unit, with more options available allowing for a wide variety of research experiments.
To help universities kick-start their quantum program, in addition, universities will have free maintenance for one year, and IQM will also provide training for running the system and learning materials accessible through IQM Academy, a user-friendly online platform. With IQM Spark, students of all levels (bachelor, master, and PhD) will have the opportunity to learn hands-on about quantum computing.
Additionally, universities can also provide their students with the skillset needed for a quantum-enabled future by leveraging both hardware and software within the learning materials. With its technical track record and world-class expertise, IQM is also committed to collaborating with universities to drive advancements in quantum science.
Dr. Kuan Yen Tan, Chief Technology Officer and Co-founder of IQM Quantum Computers, said: “Since our inception, we’ve invested in and promoted quantum education and the advancement of research, and it’s apparent that universities around the globe need critical tools like IQM Spark to train the workforce needed for the next generation. Given the potential of quantum computing, the ecosystem will require a wide range of talent across electronics, chip fabrication, hardware design, and software engineering. We are confident that our system will facilitate the learning experience and engage students with the physical system.”
“We’ve designed this offering for universities and research labs to build up their quantum expertise and we believe that our system will not only perform fundamental quantum experiments and raise interest in Science, Technology, Engineering, and Mathematics (STEM) but we will also advance university science around quantum computing in general, while addressing the shortage of talent and providing value for the job market,” Dr. Björn Pötter, Head of Product at IQM Quantum Computers, points out.
IQM has already delivered 5-qubit quantum computers to some universities and research institutions, including the VTT Technical Research Centre of Finland and the Leibniz Supercomputing Centre in Germany. The quantum computer at VTT has been connected to LUMI, Europe’s most powerful supercomputer, hosted by the CSC - IT Center for Science.
“VTT and IQM successfully collaborated in delivering Finland’s first quantum computer in 2021. The 5-qubit quantum computer enables users to take the first steps in developing quantum algorithms and learn how to utilise the new technology in practice”, said Pekka Pursula, Research Manager in Quantum Technologies at VTT.
“On-premises quantum hardware is only available from a very limited number of vendors. This fact alone makes it hard for us to provide this leading-edge hardware to our scientists. Pricing and missing learning resources make it even harder to make this leading-edge technology available for educational purposes for our students,” said Prof. Dr. Dieter Kranzlmüller, Chairman of the Board of Directors of the Leibniz Supercomputing Centre, which caters to all universities of Bavaria in Germany.
“IQM Spark will address three major challenges: availability, learning resources, and affordability. In that way, universities can give practical experience to the next generation of quantum computing experts,” he added.
“Making on-premises quantum computer hardware available to our scientists and students as a low-barrier resource will give a boost to scientific progress and educate the next generation of quantum experts. This paves the way for students in Bavarian universities, such as Ludwig Maximilian University of Munich (LMU) and Technical University of Munich (TUM) students, to become entrepreneurs in the field of quantum technologies and live up to the excellence claim of the Munich universities,” he concluded.
About IQM Quantum Computers:
IQM is the European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific, co-design approach. IQM’s commercial quantum computers include Finland’s first commercial 54-qubit quantum computer with VTT, IQM-led consortium’s (Q-Exa) HPC quantum accelerator in Germany, and IQM processors will also be used in the first quantum accelerator in Spain. IQM has over 280 employees with offices in Paris, Madrid, Munich, Singapore, and Espoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830120669/en/
Contact information
Sylwia Barthel de Weydenthal, Head of Marketing and Communications
Email: press@meetiqm.com
Mobile: +358505966629
www.meetiqm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom